CN106928275B - Preparation method of spiro amine aryl phosphorus oxide compound and intermediate and crystal form thereof - Google Patents
Preparation method of spiro amine aryl phosphorus oxide compound and intermediate and crystal form thereof Download PDFInfo
- Publication number
- CN106928275B CN106928275B CN201611178180.8A CN201611178180A CN106928275B CN 106928275 B CN106928275 B CN 106928275B CN 201611178180 A CN201611178180 A CN 201611178180A CN 106928275 B CN106928275 B CN 106928275B
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- reaction
- formula
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- -1 spiro amine aryl phosphorus oxide compound Chemical group 0.000 title claims abstract description 19
- 239000013078 crystal Chemical group 0.000 title claims abstract description 16
- 229910001392 phosphorus oxide Inorganic materials 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 19
- 238000006243 chemical reaction Methods 0.000 claims description 87
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 15
- 239000002585 base Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 9
- 239000012046 mixed solvent Substances 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical group [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 150000001340 alkali metals Chemical group 0.000 claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 235000011181 potassium carbonates Nutrition 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 3
- 125000002524 organometallic group Chemical group 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 3
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 2
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 claims description 2
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical group C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 claims description 2
- 239000000460 chlorine Chemical group 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Chemical group 0.000 claims description 2
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- PYZLRNMGUBDIHK-UHFFFAOYSA-N molecular hydrogen;nickel Chemical compound [Ni].[H][H] PYZLRNMGUBDIHK-UHFFFAOYSA-N 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 claims description 2
- 229910000105 potassium hydride Inorganic materials 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 238000001757 thermogravimetry curve Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical group CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 65
- 239000000243 solution Substances 0.000 description 45
- 239000007787 solid Substances 0.000 description 40
- 206010028980 Neoplasm Diseases 0.000 description 36
- 239000000203 mixture Substances 0.000 description 26
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 20
- 239000012065 filter cake Substances 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 15
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 238000004809 thin layer chromatography Methods 0.000 description 13
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 11
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 8
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 8
- 229960005061 crizotinib Drugs 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000000543 intermediate Chemical group 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000011729 BALB/c nude mouse Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000006242 amine protecting group Chemical group 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 102220197961 rs1057519784 Human genes 0.000 description 4
- 102220198074 rs1057519859 Human genes 0.000 description 4
- 102200048928 rs121434568 Human genes 0.000 description 4
- 102200048955 rs121434569 Human genes 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- WJZIPMQUKSTHLV-UHFFFAOYSA-N 2-ethyldecanoic acid Chemical compound CCCCCCCCC(CC)C(O)=O WJZIPMQUKSTHLV-UHFFFAOYSA-N 0.000 description 3
- UHRVNTWMSOLZCG-UHFFFAOYSA-N 2-methoxy-4-(9-methyl-3,9-diazaspiro[5.5]undecan-3-yl)aniline Chemical compound COC1=C(N)C=CC(=C1)N1CCC2(CC1)CCN(CC2)C UHRVNTWMSOLZCG-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- WQAWEUZTDVWTDB-UHFFFAOYSA-N dimethyl(oxo)phosphanium Chemical compound C[P+](C)=O WQAWEUZTDVWTDB-UHFFFAOYSA-N 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 2
- XIKUAKVCJMVXCI-UHFFFAOYSA-N 2,5-dichloro-n-(2-dimethylphosphorylphenyl)pyrimidin-4-amine Chemical compound CP(C)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl XIKUAKVCJMVXCI-UHFFFAOYSA-N 0.000 description 2
- FEPWQTGPHXVXRC-UHFFFAOYSA-N 3-(3-methoxy-4-nitrophenyl)-9-methyl-3,9-diazaspiro[5.5]undecane Chemical compound COC=1C=C(C=CC=1[N+](=O)[O-])N1CCC2(CC1)CCN(CC2)C FEPWQTGPHXVXRC-UHFFFAOYSA-N 0.000 description 2
- WLKUSVNHZXUEFO-UHFFFAOYSA-N 4-fluoro-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(F)=CC=C1[N+]([O-])=O WLKUSVNHZXUEFO-UHFFFAOYSA-N 0.000 description 2
- ZPCCNHQDFZCULN-UHFFFAOYSA-N 5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-(9-methyl-3,9-diazaspiro[5.5]undecan-3-yl)phenyl]pyrimidine-2,4-diamine Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCC2(CC1)CCN(CC2)C)OC)NC1=C(C=CC=C1)P(C)(C)=O ZPCCNHQDFZCULN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000004537 pulping Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- QJFFTQOGHIIXMC-UHFFFAOYSA-N 1'-benzylspiro[3,7-diazabicyclo[3.3.1]nonane-9,4'-piperidine]-2,4,6,8-tetrone Chemical compound O=C1NC(=O)C2C(=O)NC(=O)C1C2(CC1)CCN1CC1=CC=CC=C1 QJFFTQOGHIIXMC-UHFFFAOYSA-N 0.000 description 1
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
- MLIREBYILWEBDM-UHFFFAOYSA-M 2-cyanoacetate Chemical compound [O-]C(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-M 0.000 description 1
- DHHGHQKIKXKQGJ-UHFFFAOYSA-N 2-dimethylphosphorylaniline Chemical compound CP(C)(=O)C1=CC=CC=C1N DHHGHQKIKXKQGJ-UHFFFAOYSA-N 0.000 description 1
- UBPDKIDWEADHPP-UHFFFAOYSA-N 2-iodoaniline Chemical compound NC1=CC=CC=C1I UBPDKIDWEADHPP-UHFFFAOYSA-N 0.000 description 1
- LYYHMJMNHMDZOJ-UHFFFAOYSA-N 3-(3-methoxy-4-nitrophenyl)-3,9-diazaspiro[5.5]undecane Chemical compound COC=1C=C(C=CC=1[N+](=O)[O-])N1CCC2(CC1)CCNCC2 LYYHMJMNHMDZOJ-UHFFFAOYSA-N 0.000 description 1
- DKRVXLMWXJFVEJ-UHFFFAOYSA-N 3-benzyl-3,9-diazaspiro[5.5]undecane Chemical compound C=1C=CC=CC=1CN(CC1)CCC21CCNCC2 DKRVXLMWXJFVEJ-UHFFFAOYSA-N 0.000 description 1
- OFXQSNLQXDCJCP-UHFFFAOYSA-N 3-methyl-3,9-diazaspiro[5.5]undecane Chemical compound C1CN(C)CCC11CCNCC1 OFXQSNLQXDCJCP-UHFFFAOYSA-N 0.000 description 1
- RLVROZLNYXBHFX-UHFFFAOYSA-N 4-fluoro-2-[(5-fluoro-2-nitrophenyl)methoxymethyl]-1-nitrobenzene Chemical compound FC=1C=CC(=C(COCC2=C(C=CC(=C2)F)[N+](=O)[O-])C1)[N+](=O)[O-] RLVROZLNYXBHFX-UHFFFAOYSA-N 0.000 description 1
- LKGLPOBFCOFWMI-UHFFFAOYSA-N 5-chloro-2-N-[4-(3,9-diazaspiro[5.5]undecan-3-yl)-2-methoxyphenyl]-4-N-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCC2(CC1)CCNCC2)OC)NC1=C(C=CC=C1)P(C)(C)=O LKGLPOBFCOFWMI-UHFFFAOYSA-N 0.000 description 1
- ZMVHSKXNZKJQNK-UHFFFAOYSA-N 5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-(3-propan-2-yl-3,9-diazaspiro[5.5]undecan-9-yl)phenyl]pyrimidine-2,4-diamine Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCC2(CC1)CCN(CC2)C(C)C)OC)NC1=C(C=CC=C1)P(C)(C)=O ZMVHSKXNZKJQNK-UHFFFAOYSA-N 0.000 description 1
- NYYFWTAZWFJWJS-UHFFFAOYSA-N 5-tert-butyl-3,9-diazaspiro[5.5]undecane Chemical compound C(C)(C)(C)C1CNCCC11CCNCC1 NYYFWTAZWFJWJS-UHFFFAOYSA-N 0.000 description 1
- QQUSQTIEZXJTMQ-UHFFFAOYSA-N 9-benzyl-2,4-dioxo-3,9-diazaspiro[5.5]undecane-1,5-dicarbonitrile Chemical compound N#CC1C(=O)NC(=O)C(C#N)C11CCN(CC=2C=CC=CC=2)CC1 QQUSQTIEZXJTMQ-UHFFFAOYSA-N 0.000 description 1
- MZOUQZZYZKEBKL-UHFFFAOYSA-N 9-benzyl-3,9-diazaspiro[5.5]undecane-2,4-dione Chemical compound C1C(=O)NC(=O)CC11CCN(CC=2C=CC=CC=2)CC1 MZOUQZZYZKEBKL-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- TXHMFMUYEHVTLK-UHFFFAOYSA-N CC(C)(C)C(CN(CC1)C(O)=O)C1(CC1)CCN1C(C=C1)=CC(OC)=C1N Chemical compound CC(C)(C)C(CN(CC1)C(O)=O)C1(CC1)CCN1C(C=C1)=CC(OC)=C1N TXHMFMUYEHVTLK-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012094 cell viability reagent Substances 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- HWHZBZLGGUCCQE-UHFFFAOYSA-N methyl 9-(3-methoxy-4-nitrophenyl)-3,9-diazaspiro[5.5]undecane-3-carboxylate Chemical compound COC(=O)N1CCC2(CC1)CCN(CC2)c1ccc(c(OC)c1)[N+]([O-])=O HWHZBZLGGUCCQE-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GRMINHMYDWRRAH-UHFFFAOYSA-N tert-butyl 9-(4-amino-3-methoxyphenyl)-3,9-diazaspiro[5.5]undecane-3-carboxylate Chemical compound N1(CCC2(CC1)CCN(CC2)C1=CC(OC)=C(N)C=C1)C(=O)OC(C)(C)C GRMINHMYDWRRAH-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- PZMFITAWSPYPDV-UHFFFAOYSA-N undecane-2,4-dione Chemical compound CCCCCCCC(=O)CC(C)=O PZMFITAWSPYPDV-UHFFFAOYSA-N 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65615—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing a spiro condensed ring system of the formula where at least one of the atoms X or Y is a hetero atom, e.g. S
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses aThe invention also discloses a preparation method and a crystal form of the high-purity spiro amine aryl phosphorus oxide compound, and a method for preparing the compound shown in the formula (I) and an intermediate compound thereof.
Description
Technical Field
The invention relates to a preparation method and a crystal form of a high-purity spiro amine aryl phosphorus oxide compound, and also relates to a method for preparing a compound shown in a formula (I) and an intermediate compound thereof.
Background
PCT/CN2015/082605 describes a novel class of oral ALK inhibitors for the treatment of Anaplastic Lymphoma Kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC), including non-small cell lung cancer that is potent and resistant to Crizotinib. The structure is shown as formula (A):
crizotinib is the first ALK inhibitor approved by the FDA for the treatment of ALK-positive lung cancer. Although the initial response by Crizotinib is very effective, most patients relapse in the first year of treatment due to development of drug resistance. On 29 months 4 2014, FDA approved certiniib for the treatment of Anaplastic Lymphoma Kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC), including patients who are effective as well as resistant to crizotinib. Still other compounds are being used in clinical studies for the treatment of cancer, such as alectinib, AP-26113, and the like. Certain heterocyclic compounds have also been disclosed for use in the treatment of various cancers.
Disclosure of Invention
The invention provides a process for the preparation of a compound of formula (I),
which comprises the following steps:
wherein,
r is selected from C1-5Alkyl, preferably selected from methyl, ethyl, propyl, isopropyl, butyl;
R1selected from amino protecting groups;
x is selected from F, Cl, Br, I, OMs;
the acid is selected from organic acid or inorganic acid;
the reducing agent is selected from a heavy metal catalyst-hydrogen reduction system.
In some embodiments of the invention, R is selected from: methyl, ethyl, propyl, isopropyl, butyl.
In some embodiments of the invention, R is as defined above1Selected from: boc, Cbz, Fmoc, Alloc, Teco, methoxycarbonyl, ethoxycarbonyl, benzyl, p-methoxybenzyl.
In some embodiments of the invention, the acid is selected from: acetic acid, trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, hydrochloric acid or sulfuric acid.
In some embodiments of the present invention, the reducing agent is selected from: palladium carbon-hydrogen, raney nickel-hydrogen, palladium hydroxide-hydrogen.
In some embodiments of the present invention, the above preparation method comprises the following steps:
wherein,
the base is selected from alkali metal bases, alkaline earth metal bases, organometallic bases or organic bases.
In some embodiments of the present invention, the alkali metal base is selected from the group consisting of lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, and potassium hydride.
In some embodiments of the invention, the alkaline earth metal base is selected from calcium hydride.
In some embodiments of the present invention, the organometallic base is selected from sodium methoxide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, sodium ethoxide, and/or aluminum isopropoxide.
In some embodiments of the invention, the organic base is selected from diisopropylethylamine, triethylamine, N-methylmorpholine, 1, 8-diazabicycloundec-7-ene.
In some embodiments of the present invention, the above preparation method comprises the following steps:
in some embodiments of the present invention, the above preparation method comprises the following steps:
in some embodiments of the present invention, the above intermediate (e) can also be prepared by the following method:
in some embodiments of the invention, the compounds of formula (I) above may also be prepared by:
wherein R is2Is selected from H or C1-5An alkyl group;
r is as described above.
In some embodiments of the invention, R is as defined above2Selected from H, methyl, ethyl, propyl, butyl.
In some embodiments of the present invention, the above preparation method further comprises the following reaction scheme:
in some embodiments of the present invention, the above preparation method further comprises the following reaction
The present invention also provides compounds of the formula:
the invention also provides a crystal form A of the compound shown in the formula (II), and an XRPD pattern of the crystal form A is shown in figure 1.
In some embodiments of the invention, the XRPD pattern analysis data for form a of the compound of formula (ii) above is shown in table-1.
TABLE-1 XRPD pattern analysis data for form A of the compound of formula (II)
In some schemes of the invention, the preparation method of the crystal form A comprises the steps of adding the compound shown in the formula (II) into an organic solvent or a mixed solvent of the organic solvent and water, heating to 30-reflux temperature for dissolving, and then cooling to 0-20 ℃ within 0.5-10 hours to precipitate crystals.
In some embodiments of the present invention, the above method for preparing form a, wherein the organic solvent is selected from alcoholic solvents.
In some embodiments of the present invention, in the preparation method of the form a, the alcohol solvent is a single solvent selected from methanol, ethanol, isopropanol and/or n-butanol, or a mixed solvent of several solvents.
In some embodiments of the present invention, the mixed solvent of the organic solvent and water is preferably selected from ethanol/water and methanol/water.
In some embodiments of the invention, the volume ratio of ethanol to water is 1: 0.05-10.
Definitions and explanations
As used herein, the following terms and phrases are intended to have the following meanings unless otherwise indicated. A particular phrase or term should not be considered as ambiguous or unclear without special definition, but rather construed in a generic sense. When a trade name appears herein, it is intended to refer to its corresponding commodity or its active ingredient.
The intermediate compounds of the present invention may be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combinations thereof with other chemical synthetic methods, and equivalents thereof well known to those skilled in the art, with preferred embodiments including, but not limited to, the examples of the present invention.
The chemical reactions of the embodiments of the present invention are carried out in a suitable solvent that is compatible with the chemical changes of the present invention and the reagents and materials required therefor. In order to obtain the compounds of the present invention, it is sometimes necessary for a person skilled in the art to modify or select the synthesis steps or reaction schemes based on the existing embodiments.
An important consideration in any synthetic route planning in the art is the selection of suitable protecting groups for reactive functional groups, such as amino groups in the present invention. Greene and Wuts (protective groups In Organic Synthesis, Wiley and Sons,1991) are the authorities of this area for trained practitioners. All references cited herein are incorporated herein in their entirety.
The present invention will be specifically described below by way of examples, which are not intended to limit the present invention in any way.
All solvents used in the present invention are commercially available and can be used without further purification. The reaction is generally carried out under inert nitrogen in an anhydrous solvent. Proton NMR data were recorded on a Bruker Avance III 400(400MHz) spectrometer with chemical shifts expressed as (ppm) at the low field of tetramethylsilane. Mass spectra were measured on an agilent 1200 series plus 6110(& 1956A). LC/MS or Shimadzu MS contain a DAD: SPD-M20A (LC) and Shimadzu Micromass2020 detector. The mass spectrometer was equipped with an electrospray ion source (ESI) operating in either positive or negative mode.
The invention employs the following abbreviations: DCM represents dichloromethane; Pd/C represents palladium carbon; DMF represents N, N-dimethylformamide; EtOH stands for ethanol; MeOH represents methanol; cbz represents benzyloxycarbonyl, an amine protecting group; boc for tert-butylcarbonyl is an amine protecting group; fmoc represents fluorenyl-methoxycarbonyl, which is an amine protecting group; alloc represents an allyloxycarbonyl group, an amine protecting group; teoc represents trimethylsiloxyethyl carbonyl, which is an amine protecting group; HOAc represents acetic acid; THF represents tetrahydrofuran; boc2O represents di-tert-butyl dicarbonate; DIPEA stands for diisopropylethylamine; DIEA stands for diisopropylethylamine; DBU represents 1, 8-diazabicycloundec-7-ene; tol represents toluene; THF represents tetrahydrofuran; i-PrOH represents 2-propanol; mp represents melting point; NMP stands for N-methylpyrrolidone; AcOH represents glacial acetic acid; con. hcl (aq) stands for concentrated aqueous hydrochloric acid.
The compound is made by hand orThe software names, and the commercial compounds are under the supplier catalog name.
The powder X-ray diffraction (XRPD) method of the invention
Voltage of light pipe: 40kV, light tube current: 40mA
Scattering slit: 0.60mm
Detector slit: 10.50mm
Backscatter slit: 7.10mm
Scanning range: 4-40deg
Step length: 0.02deg
Rate: 0.1S
Sample pan rotation speed: 15rpm
Differential thermal analysis (DSC) method of the present invention
The instrument model is as follows: TA Q2000 differential scanning calorimeter
And (3) testing conditions are as follows: a sample (-1 mg) was placed in a DSC aluminum pan for testing by the method: the temperature is 25-350 ℃, and the heating rate is 10 ℃/min. The present invention is a Thermal Gravimetric Analysis (TGA) method
The instrument model is as follows: TA Q5000IR thermogravimetric analyzer
And (3) testing conditions are as follows: a sample (2-5 mg) is placed in a TGA platinum pan for testing, and the method comprises the following steps: the room temperature is 350 ℃ below zero, and the heating rate is 10 ℃/min.
The technical effects are as follows:
the process for synthesizing the compound of the formula (I) and the intermediate thereof has the following beneficial effects: the method has the advantages of low price of the initial raw materials, excellent route, low toxicity and danger of the used reagents, mild reaction conditions, simple separation and purification, easy operation and easy industrial production.
Specifically, the method comprises the following steps:
1) the raw materials of the method for preparing the compound shown in the formula (I) are conventional or common reagents, and are easily available in the market and low in price;
2) the intermediate compound (e) can be converted into two functional groups by a new intermediate compound (d) through hydrogenation reaction in one step, so that the reaction efficiency is effectively improved, and the yield is high;
3) the reaction intermediates in each step are easy to post-treat and purify, and are suitable for industrial production;
4) the A crystal form of the compound shown in the formula (II) has stable property and good patent medicine prospect.
Therefore, the invention has high industrial application value and economic value in the aspect of preparing the compound shown in the formula (I) and the intermediate thereof.
Drawings
FIG. 1 is an XRPD spectrum of Cu-Ka radiation of crystal form A of the compound of formula (II).
FIG. 2 is a DSC of form A of the compound of formula (II).
Figure 3 is a TGA profile of form a of the compound of formula (ii).
Detailed Description
For better understanding of the present invention, the following description is given with reference to specific examples, but the present invention is not limited to the specific embodiments.
Scheme 1
Example 1
Dimethylphosphineoxide
N2A solution of diethyl phosphite (400g, 2.9mol, 1 eq) in THF (4L) was cooled to 0 deg.C under protection, and a solution of MeMgBr in ether (3M,2.9L, 3eq) was added dropwise while maintaining the temperature of the reaction solution at no higher than 20 deg.C. After the addition was complete, the mixture was allowed to warm to 20 ℃ and stirred for 0.5h, and TLC (DCM: MeOH ═ 20:1) showed completion of the reaction). The reaction solution was slowly added to an aqueous potassium carbonate solution (1184g/1448mL) to quench, with an exotherm occurring during quenching, and the temperature was controlled to be 40 ℃ or lower. A white solid precipitated, the mixture was filtered, the filter cake was washed with ethanol, the filtrate was concentrated, and the solid that appeared during the concentration was filtered. To obtainThe desired product (144.09g, 63.66% yield) was a colorless viscous oil.1HNMR(400MHz,CDCl3):,7.74-7.67(m,0.5H),6.57-6.52(m,0.5H),1.56(d,J=3.6Hz,3H),1.53(d,J=3.6Hz,3H).
Example 2
(2-aminophenyl) dimethylphosphine oxide
2-iodoaniline (990.01g, 4.52mol, 1 eq.) and dimethylphosphine oxide (690g,5.2mol, 1.15 eq.), K3PO4(1.15Kg,5.42mol, 1.2 equiv.), Xantphos (130.77g,0.226mol, 0.05 equiv.) and palladium acetate (50.74g,0.226mol, 0.05 equiv.) were placed in DMF (5.5L) and water (0.55L), and the reaction mixture was heated to 110 ℃ and 125 ℃ under nitrogen and stirred for 3 hours. LCMS and TLC (PE: EA ═ 10:1, DCM: MeOH ═ 10:1) showed reaction completion. The mixture was filtered and concentrated to remove DMF, and the resulting residue was diluted with ethyl acetate (2L). Then HC/EA (4M, 2L) was added to salify the product, a large amount of solid precipitated out of the system, stirred to disperse it evenly, the solid was filtered, the filter cake was washed with acetone (0.4L x3), and the solid was dried to give the title compound (817g, yield 79.96%) as a pale yellow solid.1HNMR(400MHz,CDCl3):7.20(t,J=7.6Hz,1H),7.04(dd,J=13.6,7.6Hz,1H),6.69-6.58(m,2H),5.35(br s,2H),1.75(s,3H),1.71(s,3H).LCMS(ESI)(10-80CD):m/z:170.1[M+1].
Example 3
(2- ((2, 5-dichloropyrimidin-4-yl) amino) phenyl) dimethylphosphine oxide
To a solution of (2-aminophenyl) dimethylphosphine oxide hydrochloride (900g, 4.16mol) in ethanol (600mL) was added DIPEA (1.24Kg, 1.67L, 9.56mol, 2.3 equivalents), and the solution was observed to become clear, followed by the addition of 2,4, 5-trichloropyrimidine (915.23g, 4.99mol, 1.2 equivalents). The reaction mixture was heated to 80 ℃ and stirred for 18 hours. Tlc (etoac) showed the reaction was complete. The reaction mixture was concentrated while the reaction was cooled, and water (2L) and DCM (2L) were added and stirred for 0.5 h. After separation, the aqueous phase was extracted with DCM (500mLx3), and the combined organic phases were washed with saturated brine (2L), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. Concentrating to obtain brown solid, and pulping and washing the crude product with methyl tert-butyl etherWashing and filtration gave the title compound as a white solid (1.04Kg, yield 79%).1H NMR(400MHz,CD3OD):8.50(dd,J=8.0,4.0Hz,1H),8.35-8.28(m,1H),7.69-7.59(m,2H),7.36-7.28(m,1H),1.91(s,3H),1.88(s,3H).LCMS(ESI)(5-95AB):m/z:315.9[M+1].
Scheme 2
Example 4
9-benzyl-2, 4-dioxo-3, 9-diazaspiro [5.5] undecane-1, 5-dinitrile
Ammonium acetate (122.2g,1.59mol,0.10 eq) was added to a solution of cyanoacetate (5.38kg, 47.56mol, 3eq) in methanol at 5-8 ℃; 1-benzylpiperidine 4-one (3.0kg,15.85mol,1 eq.) was then added to the reaction mixture; then, aqueous ammonia (3.42L, 25%, 22.19mol,1.4 eq.) was added to the reaction mixture at below 10 ℃ and the mixture was stirred at 0-5 ℃ for 1 hour. The reaction mixture was then warmed to 25 ℃ (room temperature) and stirred for 20 hours. White solid is separated out in the reaction system. The reaction was heated to 50 ℃ and the pH was adjusted to 4-5 with concentrated HCl (12M) while maintaining the temperature at 70 ℃ or below. The suspension was not easily stirred, ethanol and water were added, the reaction solution was cooled to 10 ℃ with stirring, stirred for 30 minutes and filtered. The filter cake was washed with water and dried to give the title compound (4Kg, 77.73% yield) as a white solid. LCMS (ESI) (0-30AB) M/z 323.0[ M +1].
Example 5
1 '-benzyl-3, 7-diazaspiro [ bicyclo [3.3.1] nonane-9, 4' -piperidine ] -2,4,6, 8-tetraone
To an 88% sulfuric acid solution (6L, prepared by adding 5.25L of concentrated sulfuric acid to 750mL of water, with vigorous exotherm on dilution) was added 9-benzyl-2, 4-dioxo-3, 9-diazaspiro [5.5] with stirring]Undecane-1, 5-dinitrile (3.0kg,9.31mol,1 eq.) fed at a temperature of less than 60 ℃ and after the addition the reaction mixture is stirred at 60-90 ℃ for 2 hours. Then water (1.2L) was added to the reaction solution, a vigorous exotherm was generated, the reaction solution was heated to 90-100 ℃ and stirred for 1.5 hours, a large amount of solids precipitated during stirring. Then, the product is processedWater (15L) was added to the reaction mixture, and the reaction solution was cooled to 30 ℃, stirred at 30 ℃ for 12 hours, and then filtered. The filter cake was washed with cold water, the solid collected and dried to give the title compound as a white solid (3.1kg, 90% purity, 88% yield).1H NMR(400MHz,CDCl3):11.87(s,2H),9.56(br.s.,1H),7.47(s,5H),4.34(d,J=4.4Hz,2H),3.75(br.s.,1H),3.22(br.s.,4H),1.88(br.s.,4H).
Example 6
9-benzyl-3, 9-diazaspiro [5.5] undecane-2, 4-dione
To an aqueous NaOH solution (5M, 22.5L, 8 equivalents) at 15 deg.C was added 1' -benzyl-3, 7-diazaspiro [ bicyclo [3.3.1]]Nonane-9, 4' -piperidines]2,4,6, 8-tetraone (5.4kg, 14.08mol, 1 eq), then the mixture was warmed to 80 ℃ and stirred for 2 hours. The conversion of the amide of one ring of the starting material to the carboxylic acid was checked, the mixture was cooled to 60 ℃ and then concentrated hydrochloric acid was added slowly until the pH of the solution was around 7. The mixture was heated to 70-75 ℃ and concentrated HCl was added dropwise to control the rate of carbon dioxide release until the pH was adjusted to about 3-4. The mixture was heated to 75-85 ℃ and reacted further for 1 hour. After cooling the resulting suspension to 25 ℃ and stirring for 16 hours, the suspension was cooled to 10 ℃, the solid was filtered and washed with cold water. Both the product and the non-decarboxylated product are partially soluble in water, and the non-decarboxylated by-product can be removed by washing with water. The solid was dried to give the title compound as a white solid (2.67kg, purity 95%, yield 58%).1H NMR(400MHz,CDCl3):10.89(s,1H),10.60(br.s,1H),7.57(br.s.,2H),7.44(br.s.,3H),4.28(br.s.,2H),3.11(br.s.,4H),2.76(br.s.,2H),2.42(br.s.,2H),2.00-1.48(m,4H).
Example 7
3-benzyl-3, 9-diazaspiro [5.5] undecane
Slowly to 9-benzyl-3, 9-diazaspiro [5.5] at 60-70 deg.C (too slow reaction at low temperature followed by risk of temperature rise)]Lithium aluminum hydride (750g, 19.8mol, tablet, 4 equiv.) was added to a solution of undecane-2, 4-dione (1.5kg,4.86mol,1 equiv.) in tetrahydrofuran (12L), and the mixture was stirred at 70 ℃ for 16 hours, to keep the reaction solutionA few small particles of lithium aluminium hydride are seen. The mixture was cooled to 10 ℃ and quenched by the addition of water (750mL), which precipitated a large amount of solid and was difficult to stir, and ethyl acetate (5L) was added to stir the suspension followed by aqueous sodium hydroxide (1M, 750 mL). After 2 hours of continued stirring after quenching, the mixture was filtered and the filtrate was concentrated to give the title compound (750g, 50% yield) as a pale yellow oil which solidified upon cooling and was taken on to the next step without further purification.1H NMR(400MHz,CDCl3):7.34-7.27(m,5H),3.52(s,2H),2.88-2.73(m,4H),2.46-2.35(m,4H),1.58-1.51(m,4H),1.48-1.39(m,4H).
Scheme 3
Example 8
3-benzyl-9- (3-methoxy-4-nitrophenyl) -3, 9-diazaspiro [5.5] undecane
To 5-fluoro-2-nitrobenzyl ether (1.0kg, 5.84mol, 1 eq.) and 3-benzyl-3, 9-diazaspiro [5.5]]N, N-diisopropylethylamine (1.13kg, 8.77mol, 1.55 equiv.) was added to a solution of undecane (1.70kg, 5.57mol, 0.95 equiv.) in N-methylpyrrolidone (4L) and the reaction was stirred at 100 ℃ for 4 hours. TLC (dichloromethane: methanol ═ 6:1, Rf ═ 0.5) showed complete reaction. Cooling the reaction solution to room temperature, slowly adding 16L of water into the reaction solution to precipitate a large amount of solid, continuously stirring the suspension for 1 hour, filtering, adding the filter cake into 5L of ethanol, refluxing and pulping for 1 hour, cooling to room temperature, and filtering. The filter cake was again slurried with ethanol (5L) under reflux, then filtered and the filter cake dried to give the product (1.92kg, 83% yield) as a yellow solid.1H NMR(400MHz,CDCl3):8.03(d,J=9.2Hz,1H),7.37-7.28(m,5H),6.42(dd,J=9.6,2.8Hz,1H),6.30(d,J=2.4Hz,1H),3.96(s,3H),3.55(s,2H),3.45-3.34(m,4H),2.53-2.38(m,4H),1.66-1.58(m,8H).
Example 9
3-benzyl-9- (3-methoxy-4-nitrophenyl) -3-methyl-3, 9-diazaspiro [5.5] undec-3-ium
2.5L of the mixture isMethyl chloride was added to a 5L kettle (20 ℃), 0.5kg of compound (c) was added to the reaction flask (20 ℃), the temperature was programmed to 25 ± 5 ℃, and stirring was carried out until the mixture was dissolved and clarified (T ═ 25 ± 5 ℃). 0.27Kg (1.5 equivalents) of iodomethane was added dropwise to the reaction mixture over 20 + -5 min (T25 + -5 deg.C), and after the addition was complete, the mixture was stirred at 25 + -5 deg.C for 6-8 hours, and a yellow solid was continuously precipitated during the reaction. Sampling and check (TLC) while stirring (TLC: 0.5ml of the reaction solution was added to 2.5ml MeOH/2.5ml DCM, developing agent DCM: MeOH: 10:1, and the reaction was stopped by monitoring the disappearance of the starting material under UV). After completion of the reaction, the reaction solution was filtered under reduced pressure. The filter cake was slurried with 1.327Kg of dichloromethane at 25. + -. 5 ℃ for 2 hours. And drying the filter cake at 50-60 ℃ in vacuum to constant weight.1H NMR(400MHz,DMSO-d6):7.90(d,J=9.6Hz,1H),7.65-7.46(m,5H),6.64(dd,J=10.8,2.8Hz,1H),6.52(d,J=2.0Hz,1H),4.65(s,2H),3.92(s,3H),3.57-3.39(m,6H),3.31-3.20(m.,2H),2.96(s,3H),2.01-1.54(m,8H).
Example 10
2-methoxy-4- (9-methyl-3, 9-diazaspiro [5.5] undec-3-yl) aniline
1.028kg (1L) of NMP was charged to a 2L autoclave (RT), 0.1kg of compound (d) was charged to the Reactor (RT), 33.52g (3eq) of HOAc was charged to the Reactor (RT), and N2 was bubbled-5 min. 10g of wet Pd-C (50%) was added to the reaction solution, and the reaction solution was purged 4 times with H2 gas. Adjusting the reaction pressure to 1.5MPa, and heating the reaction to 80-90 ℃ under the stirring condition. Stirring at 80-90 deg.C for 10 hr (when R1 pressure is less than 1.0MPa, adding H2To 1.5MPa), central control sampling test (HPLC), sampling test (sampling method: 0.1ml was taken and dissolved in 1ml MeOH). Stopping the reaction, reducing the reaction temperature to room temperature, and then reducing the pressure of the high-pressure kettle to normal pressure; the reaction solution was filtered through celite (50g) under reduced pressure; the filter cake was washed 1 time with 0.3L DCM and the filtrate was adjusted to pH 2 with aq.hcl (1M, 0.4L); DCM (1.32Kg × 5) was added to the filtrate for extraction and TLC detection (sampling: 0.1ml of aqueous phase taken directly; developing agent: DCM/MeOH ═ 10/1, iodine development, essentially no NMP was observed). NaOH (5M, 167g) was added to the aqueous phase to adjust the pH to 10, a solid precipitated and stirring was continued for 0.5 h. Suction filtration was carried out under reduced pressure, the filter cake was washed with water (0.01L), and the filter cake was collected. Vacuum drying the solid at 60 deg.C for 5h, and checking the intermediateMeasurement (HPLC), as HPLC>At 90%, it can be directly used in the next step.1HNMR(400MHz,CD3OD):6.72(d,J=8.4Hz,1H)6.64(d,J=2.0Hz,1H)6.51(dd,J=8.4,2.0Hz,1H)3.86(s,3H)2.95-3.08(m,4H)2.37-2.59(m,4H)2.30(s,3H)1.50-1.77(m,8H)
Example 11
(2- ((5-chloro-2- ((2-methoxy-4- (9-methyl-3, 9-diazaspiro [5.5] undec-3-yl) phenyl) amino) pyrimidin-4-yl) amino) phenyl) dimethyloxy) dimethyl
NMP (102.6g) was charged into a reaction flask (room temperature), 20g of compound (e) was charged into the reaction flask with stirring, 21.85g of compound (f) was charged into the reaction flask, and 19.93g (3eq) of MeSO was added3H drop into reaction flask (temperature control)<40℃)N2Bubbling for 15-20 min. Heating the reaction to 85-90 deg.C, reacting at 85-90 deg.C for 12 hr, performing central control sampling (HPLC), and sampling (detection method: dissolving 0.1ml of reaction solution in 2ml of MeOH) to obtain compound (f)<At 2.5%, the reaction was stopped. To the reaction solution was added NaOH solution (1M, 287g) to adjust pH to 13, and a large amount of solid was precipitated and stirred for 2 h. The solid was filtered and the filter cake was washed with water (40g) until the filtrate was colourless. Collecting a filter cake, filtering, solidifying and drying (55-60 ℃) to obtain an off-white crude product, adding methanol (268g) into a reaction bottle, then adding the obtained solid, heating to 60 ℃ to dissolve, adding active carbon (5.2g) into the reaction bottle, then stirring for 2.5h at 60 ℃, cooling to 30 ℃, filtering, and concentrating the mother liquor under reduced pressure to obtain an off-green solid. MeOH (155.5g) was added to the reaction flask, followed by the solid obtained above, and heated to reflux until clear. Adding 388g of purified water into the reaction bottle, naturally cooling to 15-20 ℃, and separating out white solids. Filtration and filtration were carried out, and the solid was washed once with purified water (194 g). The filter cake was collected and dried to give the compound of formula (II) (32.5 g).1H NMR(400MHz,CD3OD):8.36(dd,J=8.0,4.4Hz,1H),8.03(s,1H),7.69(d,J=8.8Hz,1H),7.65-7.55(m,1H),7.51(dd,J=8.0 8.0Hz,1H),7.32-7.20(m,1H),6.66(d,J=2.4Hz,1H),6.45(dd,J=8.8,2.4Hz,1H),3.85(s,3H),3.18-3.06(m,4H),2.54-2.38(m,4H),2.30(s,3H),1.85(d,J=13.6Hz,6H),1.74-1.54(m,8H).
Scheme 4
Example 12
Tert-butyl ester 9- (3-methoxy-4-nitrophenyl) -3, 9-diazaspiro [5.5] undecane-3-carboxylic acid methyl ester
To tert-butyl-3, 9-diazaspiro [5.5]]To a solution of undecane-3-carboxylic acid ester (5.00g,1 eq) and 4-fluoro-2-methoxy-1-nitrobenzene (4.04g,1.2 eq) in acetonitrile (50.00mL) was added potassium carbonate (4.08g,29.49mmol,1.5 eq), and the reaction was stirred at 85 ℃ for 5 hours TLC (DCM: MeOH ═ 10:1, Rf of spiro cyclic amine ═ 0.5) showed completion of the reaction, and to the reaction was added water (30mL) and concentrated. After the organic solvent is evaporated, a solid is separated out. The mixture was filtered and the filter cake was purified by petroleum ether: beating the ethyl acetate mixed solvent (volume ratio is 5:1, 24mL), filtering, and adding petroleum ether: the ethyl acetate mixed solvent (volume ratio 20:1, 21mL) was slurried, filtered, and the filter cake was dried to give the product (7.5g, 94% yield) as a yellow solid.1H NMR(400MHz,CD3OD):,7.95(d,J=9.2Hz,1H),6.55(dd,J=9.6,2.4Hz,1H),6.48(d,J=2.4Hz,1H),3.95(s,3H),3.56-3.41(m,8H),1.72-1.65(m,4H),1.58-1.50(m,4H),1.48(s,9H).
Example 13
Tert-butyl-9- (4-amino-3-methoxyphenyl) -3, 9-diazaspiro [5.5] undecane-3-carboxylic acid ester
To tert-butyl-9- (3-methoxy-4-nitro-phenyl) -3, 9-diazaspiro [5.5] at room temperature]To a solution of undecane-3-carboxylic acid ester (4.00g,1 equiv.) and ammonium chloride (5.27g,10 equiv.) in methanol (50mL) was added zinc powder (6.45g,10 equiv.). Then stirred at room temperature for 15 minutes. TLC (petroleum ether: ethyl acetate 1:1, starting material Rf 0.6, product Rf 0.4) showed completion of the reaction. The reaction solution was filtered, the filtrate was concentrated, water (30mL) and saturated sodium carbonate solution (100mL) were added, the mixture was extracted three times with dichloromethane (50 mL/time), the combined organic layers were dried over anhydrous sodium sulfate, and the mixture was concentrated to give the title compound as a dark purple oil (3.12g, yield 84%).1HNMR(400MHz,CDCl3):6.66(d,J=8.8Hz,1H),6.55(d,J=2.4Hz,1H),6.45(dd,J=8.8,2.4Hz,1H),3.85(s,3H),3.49-3.35(m,4H),3.10-2.94(m,4H),1.74-1.63(m,4H),1.56-1.42(m,13H).
Example 14
(2- ((5-chloro-2- ((2-methoxy-4- (3, 9-diazaspiro [5.5] undecan-3-yl) phenyl) amino) pyrimidin-4-yl) amino) phenyl) dimethyl phosphine oxide
To a solution of tert-butyl-9- (4-amino-3-methoxyphenyl) -3, 9-diazaspiro [5.5] undecane-3-carboxylate (80mg,0.213mmol) in tert-butanol (3.0mL) was added (2- ((2, 5-dichloropyrimidin-4-yl) amino) phenyl) dimethylphosphine oxide (67mg,0.213mmol) and methanesulfonic acid (119mg,1.07mmol) at room temperature. Then, the reaction solution was heated to 90 ℃ under nitrogen protection and stirred for 16 hours. The reaction was concentrated and isolated by preparative isolation to give the title compound as a yellow solid (25mg, 21% yield). LCMS (ESI) (5-95AB) M/z 555.2[ M +1].
Example 15
(2- ((5-chloro-2- ((2-methoxy-4- (9-methyl-3, 9-diazaspiro [5.5] undecan-3-yl) phenyl) amino) pyrimidin-4-yl) amino) phenyl) dimethylphosphineoxide
To (2- ((5-chloro-2- ((2-methoxy-4- (3, 9-diazaspiro [5.5 ]) at room temperature]Undecane-3-yl) phenyl) amino) pyrimidin-4-yl) amino) phenyl) dimethylphosphine oxide (10mg,0.182mmol) in methanol (5.0mL) was added 37% aqueous formaldehyde (30mg,0.36mmol) followed by sodium cyanoborohydride (22mg,0.36mmol), stirred at room temperature for 1 hour and LCMS detected completion, and the reaction was quenched with (1N,0.5mL) and isolated by preparative isolation to give the title compound (4mg, 40% yield).1H NMR(400MHz,CD3OD):,8.28(s,1H),8.12(br.s.,1H),7.81-7.68(m,3H),7.65(d,J=2.0Hz,1H),7.56-7.49(m,1H),7.37(d,J=8.8Hz,1H),4.02(s,3H),3.74(br.s.,4H),3.47(d,J=12.8Hz,2H),3.24(t,J=12.8Hz,2H),2.93(s,3H),2.42-1.97(m,5H),1.93-1.75(m,9H).LCMS(ESI)(0-60AB):m/z:569.2[M+1].
Example 16
(2- ((5-chloro-2- ((4- (9-isopropyl-3, 9-diazaspiro [5.5] undecan-3-yl) -2-methoxyphenyl) amino) pyrimidin-4-yl) amino) phenyl) dimethylphosphineoxide
Example 14 preparation of a mixture of the isolated title compound (100mg, 0.18 mmol), sodium acetate borohydride (114 mg, 0.54 mmol), acetic acid (21.6 mg,0.36mmol) and acetone (20.9 mg,0.36mmol) in tetrahydrofuran (5.0mL) was stirred at 18 ℃ for 16 h. LCMS showed reaction complete. The solvent was removed by concentration under reduced pressure to give a crude product, which was purified by preparative HPLC to give the title compound (50mg, 47% yield) as a brown solid. LCMS (ESI) (10-80AB) M/z 597.3[ M +1].
Example 17
Tert-butyl-9-methyl-3, 9-diazaspiro [5.5] undecane-3-carboxylic acid ester
To a solution of tert-butyl-3, 9-diazaspiro [5.5] undecane (120mg,1 eq) in methanol (5mL) at 0 ℃ was added 37% aqueous formaldehyde (5 eq) and the mixture was warmed to 16 ℃ and stirred for 0.5 h. Sodium borohydride acetate (89mg, 3 equiv.) was then added and stirred at 16 ℃ for 12 hours. TLC detection of all conversion of the starting material, reduced pressure concentration at 35 ℃. Dichloromethane (50mL) was added for dilution, washed 3 times with water, 2 times with saturated brine (30mL), dried over sodium sulfate, filtered, and the organic phase was concentrated to give the title compound as a colorless oil (100mg, 79% yield).
Example 18
3-methyl-3, 9-diazaspiro [5.5] undecane
To a solution of tert-butyl-9-3, 9-diazaspiro [5.5] undecane (100mg,1 eq) in dichloromethane (2mL) at 0 deg.C was added trifluoromethanesulfonic acid (2mL), followed by stirring for 45 min at 16 deg.C. TLC detection of all conversion of the starting material, reduced pressure concentration at 35 ℃. Saturated sodium carbonate solution (40mL) was added, extracted 3 times with dichloromethane (40mL), washed 2 times with saturated brine (20mL), dried over sodium sulfate, filtered and the organic phase concentrated to give the title compound as a brown oil (70mg, crude).
Example 19
3- (3-methoxy-4-nitrophenyl) -9-methyl-3, 9-diazaspiro [5.5] undecane
To 3-methyl-3, 9-diazaspiro [5.5]]To a solution of undecane (4.83g,1 eq) and 4-fluoro-2-methoxy-1-nitrobenzene (5.6g,1.55 eq) in acetonitrile (100mL) was added potassium carbonate (30g, 10.2)6 equivalents), then the reaction solution is raised to 80 ℃ and stirred for 16 hours, the reaction solution is filtered after the completion of the TLC detection reaction, and the filtrate is concentrated and purified by column chromatography (eluent is petroleum ether: ethyl acetate 10:1 to 1:1) to give the title compound as a yellow solid (9.0g, crude).1H NMR(400MHz,CD3OD):7.95(d,J=9.6Hz,1H),6.56(dd,J=9.2Hz,J=2.4Hz,1H),6.49(d,J=2.4Hz,1H),3.95(s,3H),3.52–3.48(m,4H),3.09–2.91(m,4H),2.68(s,3H),1.78-1.72(m,4H),1.71-1.69(m,4H).LCMS(ESI)(0-60AB):m/z:320.2[M+1].
Example 20
2-methoxy-4- (9-methyl-3, 9-diazaspiro [5.5] undecan-3-yl) aniline
To 3- (3-methoxy-4-nitrophenyl) -9-methyl-3, 9-diazaspiro [5.5] at 10-30 ℃]Zinc powder (18.43g,281.80mmol,10.0 equiv.) was added portionwise to a solution of undecane (9.00g,1.00 equiv.) and ammonium chloride (15.07g,10.0 equiv.) in methanol (100 mL). After the addition was completed, the reaction was completed by TLC after 30 minutes of reaction at 30 ℃. The reaction solution was filtered, the filtrate was concentrated, and then a saturated sodium carbonate solution (100mL) and water (50mL) were added to conduct extraction three times with methylene chloride (80 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound as a dark purple oil (7.00g, 86% yield).1H NMR(400MHz,CD3OD):,6.72(d,J=8.4Hz,1H),6.64(d,J=2.0Hz,1H),6.51(d,J=8.4Hz,1H),3.86(s,3H),3.08-2.96(m,4H),2.58-2.45(m,4H),2.32(s,3H),1.75-1.52(m,8H).
Example 21
3- (3-methoxy-4-nitrophenyl) -3, 9-diazaspiro [5.5] undecane
Tert-butyl-9- (3-methoxy-4-nitrophenyl) -3, 9-diazaspiro [5.5]A mixed solution of undecane-3-carboxylic acid (0.7g, 1.73mmol) in trifluoroacetic acid (4mL) and dichloromethane (4mL) was stirred at 16 ℃ for 1 hour. LCMS showed completion of the reaction, aqueous sodium carbonate (50mL) was added to the mixture and extracted with dichloromethane (50mL × 2). the organic layer was extracted with anhydrous sulfuric acidSodium was dried, filtered and concentrated to give the title compound (0.7g, crude) as a yellow solid.1H NMR(400MHz,CD3OD):,7.95(d,J=9.2Hz,1H),6.55(d,J=8.8Hz,1H),6.48(s 1H),3.95(s,3H),3.51–3.49(m,4H),2.90–2.87(m,4H),1.70-1.66(m,4H),1.61-1.57(m,4H).LCMS(ESI)(0-60AB):m/z:306.0[M+1].
Example 22
3- (3-methoxy-4-nitrophenyl) -9-methyl-3, 9-diazaspiro [5.5] undecane
To a solution of example 21(0.7g, 2.3mmol) in tetrahydrofuran (10mL) at 16 deg.C was added aqueous formaldehyde (207mg, 6.9mmol, 37%) and stirred at 16 deg.C for 0.5 h. Sodium borohydride acetate (1.5g, 6.9mmol) was then added and stirred at 16 ℃ for 12 hours. LCMS showed reaction completion. The mixture was diluted with dichloromethane (60mL), filtered and concentrated to give the title compound (0.6g, 82% yield) as a yellow oil.1H NMR(400MHz,CD3OD):,7.95(d,J=9.6Hz,1H),6.56(dd,J=9.2Hz,J=2.4Hz,1H),6.49(d,J=2.4Hz,1H),3.95(s,3H),3.52–3.48(m,4H),3.09–2.91(m,4H),2.68(s,3H),1.78-1.72(m,4H),1.71-1.69(m,4H).LCMS(ESI)(0-60AB):m/z:320.2[M+1].
Example 23
2-methoxy-4- (9-methyl-3, 9-diazaspiro [5.5] undecan-3-yl) aniline
To example 22(0.6g, 1.9mmol) in EtOH/H2To a mixture of O (12mL) were added iron powder (1.1g, 18.8mmol) and ammonium chloride (1.1g, 18.8 mmol). The mixture was stirred at 80 ℃ for 2 hours. TLC (DCM: MeOH ═ 6:1) showed the reaction was complete. The reaction mixture was filtered and concentrated. The resulting residue was purified by preparative TLC (DCM: MeOH ═ 6:1) to give the title compound (400mg, 74% yield) as a green solid. 1H NMR (400MHz, CD3OD), 6.72(d, J ═ 8.4Hz,1H),6.64(d, J ═ 2.0Hz,1H),6.51(d, J ═ 8.4Hz,1H),3.86(s,3H),3.08-2.96(m,4H),2.58-2.45(m,4H),2.32(s,3H),1.75-1.52(m,8H).
Example 24
Preparation of crystal form A of compound of formula (II)
Crude (860g) of (2- ((5-chloro-2- ((2-methoxy-4- (9-methyl-3, 9-diazaspiro [5.5] undec-3-yl) phenyl) amino) pyrimidin-4-yl) amino) phenyl) dimethylphosphineoxide and purified water (8.6Kg) were added to a reaction vessel at room temperature. Dropwise adding a hydrochloric acid solution (6M, about 700mL) into the reaction kettle, and adjusting the pH value of the solution to 2-3. Dichloromethane (2.25Kg) was added to the reaction vessel, stirred for 30 minutes and allowed to stand for stratification. After the organic layer was separated, dichloromethane (2.25Kg) was added to the reaction vessel, stirred for 30 minutes, allowed to stand for delamination, and the aqueous layer was collected.
The pH of the aqueous layer was adjusted to 10-11 with an aqueous sodium hydroxide solution (1N) to precipitate a white solid. Stirring was continued for 30 minutes and then filtered. The filter cake was dried under vacuum at 60 ℃ for 22 h to give a white solid (830 g).
The solid (526g) obtained above, ethanol (1.66Kg) and purified water (1.05Kg) were charged into a reaction vessel, and mixed with stirring. The mixture was warmed to 84 ℃ and stirred at this temperature until the mixture was clear.
The system was slowly cooled to room temperature, stirred for 16 hours and filtered. The filter cake was washed once with a mixed solvent (100g) of ethanol/water (volume ratio, 2/1). The filter cake was dried under vacuum at 60 ℃ for 21 hours to give form a of the compound of formula (ii) (472g, 99.05% purity, 89% yield) as a white solid.
Solubility test of crystal form A in different solvents
About 2mg of the sample was weighed into a 1.5mL liquid phase vial, and the following solvents were added stepwise using a pipette, respectively, and dissolved by shaking manually. The test was conducted at room temperature and the dissolution was judged by the naked eye and the results are shown in Table 2.
Table 2 solubility results of form a in different solvents
Biochemical experiments
Experimental Material
Enzyme: ALK wild type, ALK C1156Y and ALK L1196M were all purchased from Carna Biosciences (Japan), and EGFR T790M/L858R was purchased from Life technology (Madison, Wis.).
HTRF kit: substrates purchased from Cis-Bio International, including Eu-labeled TK1 antibody, XL665 and biotin-labeled TK1 polypeptide.
A detection instrument: envision (perkinelmer).
Experimental methods
Test compounds were diluted in 3-fold gradient to obtain 11 doses at final concentrations from 1uM to 0.017 nM.
10ul wild type ALK enzyme reaction mixture system: 0.5nM wild type ALK,1uM biotin-TK1peptide,30uM ATP. Reaction buffer: 50mM Hepes (pH7.5),10mM MgCl2,0.01mM NaV3VO4. the reaction plate is a whitet Proxiplate 384-Plus plate (Perkinelmer), and the reaction is carried out at room temperature for 90 minutes.
10ul ALK C1156Y enzyme reaction mixture system, 0.15nM ALK C1156Y,1uM biotin-TK1peptide,30uM ATP. Reaction buffer: 50mM Hepes (pH7.5),10mM MgCl2,0.01mM NaV3VO4. the reaction plate is white Proxiplate 384-Plus plate (Perkinelmer). The reaction was carried out at room temperature for 60 minutes.
10ul ALK L1196M enzyme reaction mixture system, 0.15nM ALK L1196M,1uM biotin-TK1peptide,30uM ATP. Reaction buffer: 50mM Hepes (pH7.5),10mM MgCl2,0.01mM NaV3VO4. the reaction plate is white Proxiplate 384-Plus plate (Perkinelmer), and the reaction is carried out at room temperature for 60 minutes.
10ul EGFR T790M/L858R enzyme reaction mixture system, 0.08nM EGFR T790M/L858R,1 uMbitin-TK 1peptide, 20uM ATP. Reaction buffer: 50mM Hepes (pH7.5),10mM MgCl2,0.01mM NaV3VO4. the reaction plate is white Proxiplate 384-Plus plate (Perkinelmer). The reaction was carried out at room temperature for 60 minutes.
Detection reaction: 10ul of detection reagent was added to the reaction plate at a final concentration of 2nM for antibodies and 62.5nM for XL 665. Incubate at room temperature for 60 minutes. Envision read plate.
Data analysis
The readings were converted to inhibition (%) (Min-Ratio)/(Max-Min) × 100% by the following formula. IC50 data were measured by 4-parameter curve fitting (Model 205in XLFIT5, iDBS).
Cell experiments
Experimental Material
RPMI1640, fetal bovine serum, penicillin/streptomycin solution, all purchased from Life Technology (Madison, Wis.). Cell Titer-Glo luminescence Cell viability reagents were purchased from Promega (Madison, Wis.). Karpas299 Cell line was purchased from European Collection of Cell Cultures (ECACC). Plate reading instrument: envision (perkinelmer).
Experimental methods
384 well plates, each of 2500 Karpas-299 cells, 45ul volume. The cells were incubated overnight at 37 ℃ in a CO2 incubator. Test compounds were diluted in 3-fold gradients to obtain 10 dose concentrations from 2.5mM to 0.127uM, in duplicate wells. The middle plate was filled with 49ul of medium per well. Transfer 1ul of compound from the gradient dilution compound plate to the middle plate and mix well. Then 5ul of liquid was taken from the middle plate and transferred to the cell plate. The cells were further cultured in a CO2 incubator for 72 hours. After 72 hours, 25ul of detection reagent was added. Incubate for 10 min at room temperature and Envision read the plate.
Data analysis
The reading was converted into an inhibition ratio (%)(Max-Sample)/(Max-Min)*100%. IC50 data were measured by 4-parameter curve fitting (Model 205in XLFIT5, iDBS).
Data for ALK enzyme inhibition IC50, ALK L1196M enzyme inhibition IC50, ALK C1156Y enzyme inhibition IC50, EGFR T790M/L858R enzyme inhibition IC50, and ALK IC50 of Karpas-299 cells of the compounds of the invention are shown in the following tables. Compounds with IC50 between 1-100nM are indicated by +++.
In vivo efficacy study
The following in vivo pharmacodynamic data show that the compound of the invention shows unexpected antitumor activity and tumor volume reduction compared with the reference compound AP26113 on both a wild type LU-01-0015 lung cancer patient-derived xenograft (PDX) model (BALB/c nude mice) and a LU-01-0319Crizotinib drug-resistant model (BALB/c nude mice). For example, in the LU-01-0015 model, representative compounds of formula (II) are23 days after administration (25 mg/kg), the tumor volume was about 277mm from the very beginning3Reduced to 30-45mm3Whereas AP26133 is reduced to only 119mm3。
1. In vivo drug effect experiment is carried out on xenograft (PDX) BALB/c nude mice with source of subcutaneous implantation LU-01-0015 lung cancer patient
BALB/c nude mice, female, 6-8 weeks, weighing about 18-22 grams, were kept in a special pathogen-free environment in a single ventilated cage (5 mice per cage). All cages, bedding and water were sterilized prior to use. All animals were free to obtain a standard certified commercial laboratory diet. There were 80 mice purchased from BK laboratory animal Co, Shanghai, LTD for study. Each mouse was implanted subcutaneously in tumor tissue (20-30 cubic millimeters) in the right flank for tumor growth. The experiment was started when the mean tumor volume reached about 250-300 cubic millimeters. The test compounds were administered orally at 25mg/kg daily. Tumor volume was measured every 3 days with a two-dimensional caliper, the volume being measured in cubic millimeters and calculated by the following formula: v ═ 0.5a × b2, where a and b are the major and minor diameters of the tumor, respectively. The anti-tumor efficacy was determined by dividing the mean tumor gain volume of animals treated with the compound by the mean tumor gain volume of untreated animals.
2. Transplanting LU-01-0319 xenograft tumor under skin, and performing in vivo drug effect experiment on Crizotinib-resistant BALB/c nude mouse
Initially, a LU-01-0319 xenograft tumor model obtained from surgically excised clinical specimens and implanted in nude mice, defined as lot P0 (LU-01-0319-P0). The next batch of tumor implantations from P0 was defined as batch P1 (LU-01-0319-P1). FP3 was recovered from P2 and the next batch was defined as batch FP4 from FP3 tumor implantation. Tumor-bearing mice were treated with Crizotinib about 2-3 weeks after tumor implantation when the tumor size reached about 300mm 3. A tumor with a sustained increase was defined as the LU-01-0319 anti-tumor model. BALB-c nude mice, female, 6-8 weeks, weighing about 18-22 grams, 75 mice were used for the study, purchased from BK Laboratory Animal co. Tumor sections of LU-01-0319R FP6 (about 30 mm) were implanted subcutaneously in the right flank of each mouse3) And is used for the growth of tumors. About 2-3 weeks after tumor implantation, the tumor size reaches about 300mm3In this case, tumor-bearing mice were treated with Crizotinib (10/25/50/75 mg/kg). The dose of Crizotinib may be varied as appropriate depending on the size of the tumor. When the average tumor volume reaches about-500 mm3Experimental studies were started. Test compounds were administered orally once daily. Tumor size was measured twice weekly, in two dimensions with calipers, and volume was calculated using the following formula: v ═ 0.5a x b2, where a and b are the major and minor diameters of the tumor, respectively. The anti-tumor efficacy was determined by dividing the mean tumor gain volume of animals treated with the compound by the mean tumor gain volume of untreated animals.
Administration amount is 3 mg/Kg; administration amount 10 mg/Kg; 25mg/Kg
3. In vivo drug effect experiment is carried out on a xenograft (PDX) BALB/c nude mouse from a patient with LU-01-0319 lung cancer implanted subcutaneously
BALB/c nude mice, female, 6-8 weeks, weighing about 18-22 grams, were kept in a special pathogen-free environment in a single ventilated cage (5 mice per cage). All cages, bedding and water were sterilized prior to use. All animals were free to obtain a standard certified commercial laboratory diet. There were 80 mice purchased from BK laboratory animal Co, Shanghai, LTD for study. Each mouse was implanted subcutaneously in tumor tissue (20-30 cubic millimeters) in the right flank for tumor growth. The experiment was started when the mean tumor volume reached about 250-300 cubic millimeters. The test compounds were administered orally at 10mg/kg daily. Tumor volume was measured every 3 days with a two-dimensional caliper, the volume being measured in cubic millimeters and calculated by the following formula: v ═ 0.5a × b2, where a and b are the major and minor diameters of the tumor, respectively. The anti-tumor efficacy was determined by dividing the mean tumor gain volume of animals treated with the compound by the mean tumor gain volume of untreated animals.
The compounds of formula (II) are useful in the treatment of a variety of cancers including anaplastic large cell lymphoma, non-small cell lung cancer, diffuse large B-cell lymphoma, inflammatory myofibroblast tumors, neuroblastoma, thyroid undifferentiated carcinoma and rhabdomyosarcoma. The compounds of formula (II) may be used as monotherapy or in combination with other chemotherapeutic agents.
Claims (15)
1. A process for the preparation of a compound of formula (I),
which comprises the following steps:
wherein,
r is selected from C1-5An alkyl group;
R1selected from amino protecting groups;
x is selected from fluorine, chlorine, bromine, iodine and methyl sulfonate;
the acid is selected from organic acid or inorganic acid;
the reducing agent is selected from palladium carbon-hydrogen, Raney nickel-hydrogen and palladium hydroxide-hydrogen.
2. The process according to claim 1, wherein R is selected from methyl, ethyl, propyl, butyl;
R1selected from: tert-butoxycarbonyl, benzyloxycarbonyl, fluorenylmethyloxycarbonyl, allyloxycarbonyl, trimethylsiloxyethoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, benzyl and p-methoxybenzyl;
the acid is selected from: acetic acid, trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, hydrochloric acid or sulfuric acid.
3. The production method according to claim 2, wherein the propyl group is an isopropyl group.
5. The preparation method according to claim 4, wherein the alkali metal base is selected from the group consisting of lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium hydride, potassium hydride;
the alkaline earth metal base is selected from calcium hydride;
the organic metal base is selected from sodium methoxide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, sodium ethoxide and/or aluminium isopropoxide;
the organic base is selected from diisopropylethylamine, triethylamine, N-methylmorpholine and 1, 8-diazabicycloundecen-7-ene.
7. The method of claim 6, wherein R2Selected from H, methyl, ethyl, propyl, butyl.
11. Form a of a compound of formula (ii) having an X-ray powder diffraction pattern with characteristic diffraction peaks at the following 2 Θ angles: 8.752 °, 9.602 °, 10.35 °, 11.491 °, 12.383 °, 13.978 °, 14.474 °, 14.867 °, 15.992 °, 16.799 °, 17.999 °, 18.28 °, 19.009 °, 20.33 °, 20.704 °, 21.532 °, 22.185 °, 22.834 °, 23.288 °, 23.916 °, 24.924 °, 25.381 °, 25.931 °, 26.402 °, 27.21 °, 28.373 °, 29.007 °, 29.419 °, 31.829 °, 32.264 °, 34.214 °, 38.357 °,
13. The crystalline form a according to any one of claims 10-12, characterized in that: the crystal form has a DSC pattern shown in figure 2.
14. The crystalline form a according to any one of claims 10-12, characterized in that: the crystalline form has a TGA profile as shown in figure 3.
15. The preparation method of the crystal form A according to any one of claims 10 to 14, which comprises the steps of adding the compound shown in the formula (II) into an organic solvent or a mixed solvent of the organic solvent and water, heating to 30 ℃ to reflux temperature for dissolution, and then cooling to 0-20 ℃ within 0.5-10 hours to precipitate crystals; wherein the organic solvent is selected from one single solvent or a mixed solvent of several solvents of ethanol, isopropanol and/or n-butanol; the mixed solvent of the organic solvent and water is selected from ethanol/water, and the volume ratio of the ethanol to the water is 1: 0.05-10.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511018974 | 2015-12-29 | ||
CN2015110189743 | 2015-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106928275A CN106928275A (en) | 2017-07-07 |
CN106928275B true CN106928275B (en) | 2020-10-02 |
Family
ID=59444600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611178180.8A Active CN106928275B (en) | 2015-12-29 | 2016-12-19 | Preparation method of spiro amine aryl phosphorus oxide compound and intermediate and crystal form thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106928275B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107522742B (en) * | 2017-10-20 | 2019-10-18 | 常州工程职业技术学院 | A kind of homogeneous " one kettle way " preparation method of Brigatinib key intermediate |
CN110305161A (en) * | 2018-03-20 | 2019-10-08 | 暨南大学 | 2- amino-metadiazine compound and its application |
CN110407877A (en) * | 2018-04-28 | 2019-11-05 | 齐鲁制药有限公司 | The polymorphic of novel loop coil aryl phosphorous oxides |
CN109776607B (en) * | 2019-02-21 | 2021-06-04 | 青岛海洋生物医药研究院 | Aryl phosphorus oxygen and aryl phosphorus sulfur compounds, and preparation method and application thereof |
CN110713497A (en) * | 2019-10-30 | 2020-01-21 | 成都海杰亚医药科技有限公司 | Preparation method of Brigatinib intermediate 2-aminophenyldimethylphosphine oxide |
WO2023280090A1 (en) * | 2021-07-05 | 2023-01-12 | 齐鲁制药有限公司 | Pharmaceutical composition, and preparation method therefor and application thereof |
WO2024027565A1 (en) * | 2022-08-01 | 2024-02-08 | 齐鲁制药有限公司 | Crystal form of spirocyclic amine aryl phosphorus oxide compound and preparation method therefor |
CN115521309A (en) * | 2022-09-16 | 2022-12-27 | 思科(深圳)药物研发有限公司 | Iruaoke impurity and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101687822A (en) * | 2007-07-06 | 2010-03-31 | 安斯泰来制药株式会社 | Di(arylamino)aryl compound |
CN1788001B (en) * | 2003-03-14 | 2010-09-22 | 诺瓦提斯公司 | 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
WO2012053606A1 (en) * | 2010-10-22 | 2012-04-26 | アステラス製薬株式会社 | Arylaminoheterocyclic carboxamide compound |
CN104144915A (en) * | 2012-02-28 | 2014-11-12 | 安斯泰来制药有限公司 | Nitrogen-containing aromatic heterocyclic compound |
CN105330698A (en) * | 2014-07-04 | 2016-02-17 | 南京明德新药研发股份有限公司 | Spiro aryl phosphorus oxide or sulfide |
-
2016
- 2016-12-19 CN CN201611178180.8A patent/CN106928275B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1788001B (en) * | 2003-03-14 | 2010-09-22 | 诺瓦提斯公司 | 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
CN101687822A (en) * | 2007-07-06 | 2010-03-31 | 安斯泰来制药株式会社 | Di(arylamino)aryl compound |
WO2012053606A1 (en) * | 2010-10-22 | 2012-04-26 | アステラス製薬株式会社 | Arylaminoheterocyclic carboxamide compound |
CN104144915A (en) * | 2012-02-28 | 2014-11-12 | 安斯泰来制药有限公司 | Nitrogen-containing aromatic heterocyclic compound |
CN105330698A (en) * | 2014-07-04 | 2016-02-17 | 南京明德新药研发股份有限公司 | Spiro aryl phosphorus oxide or sulfide |
Also Published As
Publication number | Publication date |
---|---|
CN106928275A (en) | 2017-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106928275B (en) | Preparation method of spiro amine aryl phosphorus oxide compound and intermediate and crystal form thereof | |
US10494373B2 (en) | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor | |
CN108699062B (en) | Tetrahydropyranyl amino-pyrrolopyrimidinones and methods of use thereof | |
AU2014225155B2 (en) | Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof | |
WO2012098070A1 (en) | Quinoline dyrk1 inhibitors | |
CA2711769A1 (en) | Method for preparing adenine compound | |
CN107955019B (en) | Salt form and crystal form of EGFR inhibitor and preparation method thereof | |
EP2861231B1 (en) | Inhibitor of jak1 and jak2 | |
WO2020200191A1 (en) | Egfr inhibitors, compositions and methods there of | |
CN116546985A (en) | Pyridopyrimidine derivative and preparation method and application thereof | |
CN111606889B (en) | Process for the preparation of 4- (1-cyclopropyl-1H-indol-3-yl) -N-phenylpyrimidin-2-amine derivatives | |
WO2017071607A1 (en) | CRYSTAL FORM OF 4H-PYRAZOLO[1,5-α]BENZOIMIDAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND INTERMEDIATE THEREOF | |
US20240166640A1 (en) | Heteroaryl derivative compounds, and uses thereof | |
KR20200090828A (en) | Pyrazolopyridinone compounds | |
CN110407877A (en) | The polymorphic of novel loop coil aryl phosphorous oxides | |
EP3438096B1 (en) | Manufacturing process for 1-(arylmethyl) quinazoline-2,4 (1h, 3h)-dione | |
US11993598B2 (en) | Compounds for inhibiting EGFR kinase, preparation methods and uses thereof | |
US20130123501A1 (en) | Process for the preparation of the compound osi-906 | |
CN111808077B (en) | Piperazine amide derivatives, process for their preparation and their use in medicine | |
CN109071530B (en) | Fused pyrimidine piperidine ring derivatives, and preparation method and application thereof | |
CA3132628A1 (en) | Inhibiting cyclic amp-responsive element-binding protein (creb) | |
CN116283971B (en) | Indoline compound containing condensed heterocyclic structure, and preparation method and application thereof | |
CN112194653B (en) | Pyrimidine benzimidazole heterozygote, preparation method and colon cancer resisting application | |
CN115380024A (en) | Crystal forms of diazaspiro pyran compounds | |
AU2023246405A1 (en) | Compound used as kinase inhibitor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230915 Address after: 250100 Xinlu Street 317, Jinan High-tech Zone, Shandong Province Patentee after: Qilu Pharmaceutical Co.,Ltd. Patentee after: Shandong Anhong Pharmaceutical Co.,Ltd. Address before: 250100 No. 243 industrial North Road, Shandong, Ji'nan Patentee before: Qilu Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |